Core Viewpoint - CRISPR Therapeutics AG is at the forefront of gene editing, having received approval for its first gene editing treatment, CASGEVY, which targets sickle cell disease and beta-thalassemia [2][4]. Company Overview - CRISPR Therapeutics' stock is currently trading at approximately $36.31, showing little change since 2018, and investors from 2020 and 2021 may be facing losses [3][11]. - The company has a significant cash reserve of approximately $1.86 billion as of March 31, 2025, which is expected to support future growth [8]. Product and Market Potential - CASGEVY has been approved in eight jurisdictions and has 65 authorized treatment centers globally, with expectations for significant patient initiation growth by 2025 [6]. - The total addressable market for CASGEVY is estimated to be around 60,000 patients, although this is small compared to larger markets for diseases like cancer and diabetes [6][7]. Future Outlook - The company anticipates that 2026 will mark a turning point, generating enough revenue from CASGEVY to support sustainable growth for ongoing and future clinical trials [8]. - Analysts have a 12-month price target for CRISPR Therapeutics stock at $71.75, indicating a potential upside of 97.60% from the current price [10][12]. Investment Sentiment - Despite the current challenges, over 69% of CRSP stock is owned by institutional investors, and buying has outpaced selling for the last nine quarters [11][12]. - The stock is rated as a Moderate Buy by analysts, although it is not currently considered a top investment compared to other stocks [12][14].

My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.CRISPR Therapeutics currentl ...

With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks by combining clinical insight with rigorous valuation methods. He specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to uncover asymmetric risk-reward. His focus is on translating complex science and market dynamics into actionable investment theses. His influences include Superforecasting and Fooled by Randomness.Stay up to date with Stephen's latest thoughts and investment insights ...

CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.The company disclosed data regarding the first 10 patients across its Phase 1 first-in-human dose escalation trial, targeting ANGPTL3 in four patient groups with elevated low-density lipoprotein (LDL), triglyceride (TG), or both.The data comes from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2[0.3 mg/kg], DL3 [0.6 ...

CRISPR Therapeutics (CRSP) reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.27 per share. In the year-ago period, the company had recorded a loss of $1.43 per share. Total revenues, comprising only grant revenues, amounted to $0.86 million in the quarter, which significantly missed the Zacks Consensus Estimate of $5 million. In the year-ago period, the company recorded total revenues of $0.5 million, which also comprised grant revenues. S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (A ...

Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain mom ...

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain momentum; more than 65 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 90 patients have had cells collected across all regions; new patient in ...

Group 1 - Gene therapy stocks, including CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA), experienced significant volatility in Q1 2025, resulting in year-to-date share price declines of -2.82% and -24.19%, respectively [1] - The decline in share prices may be partially linked to the overall instability in the biotechnology sector [1] - The analysis focuses on the potential of novel treatments, particularly in Cell & Gene Therapies (CGT), and their ability to generate returns for shareholders [1]